HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

RMTI

Rockwell Medical, Inc. (NASDAQ)

Healthcare — Drug Manufacturers - Specialty & Generic

Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. In addition, it offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

None 2 analysts
$0.59
$-0.06 (-9.23%)
Target: $30.00 (4984.7%)
Sign in to add RMTI to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$20.49M
P/E Ratio (TTM)-
Forward P/E74.14
EPS (TTM)$-1.50
Dividend Yield-
Profit Margin-7.99%
Revenue Growth-8.30%
ROE-16.04%
Debt/Equity40.13
Recommendation None
Analyst Target$30.00
Analysts2
Indexes NASDAQ

Technical Indicators

RSI (14)39.4
Beta1.62
SMA 20-
SMA 40-
52-Week High$21.00
52-Week Low$5.19
50-Day Avg$7.49
200-Day Avg$9.57
Avg Volume30.6K
Volume73.5K

Performance Analysis

NEUTRAL

RMTI presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($5.19), which could present a value opportunity.
~ RSI at 39.4 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
- Revenue declined 8.3% year-over-year.
- Operating at a loss with -8.0% margin.
~ Wall Street consensus is "none" from 2 analysts.
+ Average analyst target of $30.00 implies 4984.7% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:29 UTC

Back to Screener Export Report